J Korean Med Assoc.  2018 Mar;61(3):207-213. 10.5124/jkma.2018.61.3.207.

Antimicrobial therapy for methicillin-resistant Staphylococcus aureus

• Choo EJ

• KMID: 2406975
• DOI: http://doi.org/10.5124/jkma.2018.61.3.207

Abstract

Methicillin-resistant Staphylococcus aureus (MRSA) is a common cause of healthcare-associated infections. Recently, community-associated MRSA has emerged, manifesting as skin and soft tissue infections in patients without any prior healthcare contact. Vancomycin, a glycopeptide in clinical use for more than 50 years, still remains an acceptable treatment option. However, significant concerns have been raised regarding the decreasing susceptibility of S. aureus to this agent. The growing awareness of the limitations of vancomycin has served as an impetus for development of newer agents. There has been an increase in the number of agents available to treat MRSA infections. Linezolid, daptomycin, telavancin, and ceftaroline have received regulatory approval in the last decade for the treatment of MRSA. Although these drugs do have certain differentiating attributes and may offer some advantages over vancomycin, they also have significant limitations.

Keyword

Methicillin-resistant Staphylococcus aureus; Vancomycin; Treatment

MeSH Terms

Daptomycin
Delivery of Health Care
Humans
Linezolid
Methicillin Resistance*
Methicillin-Resistant Staphylococcus aureus*
Skin
Soft Tissue Infections
Vancomycin
Daptomycin
Linezolid
Vancomycin

Reference

1. Kang CI, Song JH. Antimicrobial resistance in Asia: current epidemiology and clinical implications. Infect Chemother. 2013; 45:22–31.

2. Choo EJ, Chambers HF. Treatment of methicillin-resistant Staphylococcus aureus bacteremia. Infect Chemother. 2016; 48:267–273.

3. Cunha BA. Methicillin-resistant Staphylococcus aureus: clinical manifestations and antimicrobial therapy. Clin Microbiol Infect. 2005; 11:Suppl 4. 33–42.

4. Song JY, Kim WJ. Antimicrobial therapy of multidrug-resistant gram-positive bacterial infections. Korean J Med. 2006; 71:Suppl 2. S786–S803.

5. Fridkin SK, Hageman JC, Morrison M, Sanza LT, Como-Sabetti K, Jernigan JA, Harriman K, Harrison LH, Lynfield R, Farley MM. Active Bacterial Core Surveillance Program of the Emerging Infections Program Network. Methicillin-resistant Staphylococcus aureus disease in three communities. N Engl J Med. 2005; 352:1436–1444.

6. Kim JS, Kim UJ. Community-acquired MRSA. Infect Chemother. 2004; 36:Suppl 2. 137–140.

7. Kim M, Kim NJ. Antimicrobial resistance and treatment update of skin and soft tissue infections. Korean J Med. 2011; 81:699–707.

8. Liu C, Bayer A, Cosgrove SE, Daum RS, Fridkin SK, Gorwitz RJ, Kaplan SL, Karchmer AW, Levine DP, Murray BE, J Rybak M, Talan DA, Chambers HF. Infectious Diseases Society of America. Clinical practice guidelines by the infectious diseases society of America for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children. Clin Infect Dis. 2011; 52:e18–e55.

9. Kang CI. What's new in the management of bacterial infections in the era of multidrug-resistant bacteria? J Korean Soc Transplant. 2013; 27:81–86.

10. Park KH, Kim ES, Kim HS, Park SJ, Bang KM, Park HJ, Park SY, Moon SM, Chong YP, Kim SH, Lee SO, Choi SH, Jeong JY, Kim MN, Woo JH, Kim YS. Comparison of the clinical features, bacterial genotypes and outcomes of patients with bacteraemia due to heteroresistant vancomycin-intermediate Staphylococcus aureus and vancomycin-susceptible S. aureus. J Antimicrob Chemother. 2012; 67:1843–1849.

11. Ruef C. Epidemiology and clinical impact of glycopeptide resistance in Staphylococcus aureus. Infection. 2004; 32:315–327.

12. van Hal SJ, Paterson DL, Lodise TP. Systematic review and meta-analysis of vancomycin-induced nephrotoxicity associated with dosing schedules that maintain troughs between 15 and 20 milligrams per liter. Antimicrob Agents Chemother. 2013; 57:734–744.

13. Yoon YK, Park DW, Sohn JW, Kim HY, Kim YS, Lee CS, Lee MS, Ryu SY, Jang HC, Choi YJ, Kang CI, Choi HJ, Lee SS, Kim SW, Kim SI, Kim ES, Kim JY, Yang KS, Peck KR, Kim MJ. Multicenter prospective observational study of the comparative efficacy and safety of vancomycin versus teicoplanin in patients with health care-associated methicillin-resistant Staphylococcus aureus bacteremia. Antimicrob Agents Chemother. 2014; 58:317–324.

14. Wunderink RG, Niederman MS, Kollef MH, Shorr AF, Kunkel MJ, Baruch A, McGee WT, Reisman A, Chastre J. Linezolid in methicillin-resistant Staphylococcus aureus nosocomial pneumonia: a randomized, controlled study. Clin Infect Dis. 2012; 54:621–629.

15. Walkey AJ, O'Donnell MR, Wiener RS. Linezolid vs glycopeptide antibiotics for the treatment of suspected methicillin-resistant Staphylococcus aureus nosocomial pneumonia: a meta-analysis of randomized controlled trials. Chest. 2011; 139:1148–1155.

16. Bassetti M, Vitale F, Melica G, Righi E, Di Biagio A, Molfetta L, Pipino F, Cruciani M, Bassetti D. Linezolid in the treatment of Gram-positive prosthetic joint infections. J Antimicrob Chemother. 2005; 55:387–390.

17. Schrenzel J, Harbarth S, Schockmel G, Genne D, Bregenzer T, Flueckiger U, Petignat C, Jacobs F, Francioli P, Zimmerli W, Lew DP. Swiss Staphylococcal Study Group. A randomized clinical trial to compare fleroxacinrifampicin with flucloxacillin or vancomycin for the treatment of staphylococcal infec-tion. Clin Infect Dis. 2004; 39:1285–1292.

18. San Juan R, Garcia-Reyne A, Caba P, Chaves F, Resines C, Llanos F, Lopez-Medrano F, Lizasoain M, Aguado JM. Safety and efficacy of moxifloxacin monotherapy for treatment of orthopedic implant-related staphylococcal infections. Antimicrob Agents Chemother. 2010; 54:5161–5166.

19. Perlroth J, Kuo M, Tan J, Bayer AS, Miller LG. Adjunctive use of rifampin for the treatment of Staphylococcus aureus infections: a systematic review of the literature. Arch Intern Med. 2008; 168:805–819.

20. Kim BN. Oral agents for the treatment of orthopedic infections caused by methicillin-resistant Staphylococci. Infect Chemother. 2011; 43:322–338.

21. Shelburne SA, Musher DM, Hulten K, Ceasar H, Lu MY, Bhaila I, Hamill RJ. In vitro killing of community-associated methicillin-resistant Staphylococcus aureus with drug combinations. Antimicrob Agents Chemother. 2004; 48:4016–4019.

22. Garau J, Bouza E, Chastre J, Gudiol F, Harbarth S. Management of methicillin-resistant Staphylococcus aureus infections. Clin Microbiol Infect. 2009; 15:125–136.

23. Lew DP, Waldvogel FA. Osteomyelitis. Lancet. 2004; 364:369–379.

24. Coombs RR. Fusidic acid in staphylococcal bone and joint infection. J Antimicrob Chemother. 1990; 25:Suppl B. 53–60.

25. Stein GE, Craig WA. Tigecycline: a critical analysis. Clin Infect Dis. 2006; 43:518–524.

26. Fowler VG Jr, Boucher HW, Corey GR, Abrutyn E, Karchmer AW, Rupp ME, Levine DP, Chambers HF, Tally FP, Vigliani GA, Cabell CH, Link AS, DeMeyer I, Filler SG, Zervos M, Cook P, Parsonnet J, Bernstein JM, Price CS, Forrest GN, Fätkenheuer G, Gareca M, Rehm SJ, Brodt HR, Tice A, Cosgrove SE. S. aureus Endocarditis and Bacteremia Study Group. aureus Endocarditis and Bacteremia Study Group. Daptomycin versus standard therapy for bacteremia and endocarditis caused by Staphylococcus aureus. N Engl J Med. 2006; 355:653–665.

27. Moore CL, Osaki-Kiyan P, Haque NZ, Perri MB, Donabedian S, Zervos MJ. Daptomycin versus vancomycin for bloodstream infections due to methicillin-resistant Staphylococcus aureus with a high vancomycin minimum inhibitory concentration: a case-control study. Clin Infect Dis. 2012; 54:51–58.

28. Anstead GM, Owens AD. Recent advances in the treatment of infections due to resistant Staphylococcus aureus. Curr Opin Infect Dis. 2004; 17:549–555.

29. Stryjewski ME, Chu VH, O'Riordan WD, Warren BL, Dunbar LM, Young DM, Vallee M, Fowler VG Jr, Morganroth J, Barriere SL, Kitt MM, Corey GR. FAST 2 Investigator Group. Telavancin versus standard therapy for treatment of complicated skin and skin structure infections caused by gram-positive bacteria: FAST 2 study. Antimicrob Agents Chemother. 2006; 50:862–867.